Skip to main content
SpringerLink
Log in
Book cover

Skin Cancer Management pp 203–216Cite as

Practical Management of Melanoma

  • Chapter
  • First Online:

  • 1193 Accesses

Abstract

Melanoma incidence continues to rise at an alarming rate. More than 62,000 new cases and over 8,000 deaths were predicted for 2008 in the United States.1 Today, approximately one out of every six cancer survivors is a melanoma survivor.1 This chapter presents a broad and practical approach to the subject of treating a patient with suspected or proven melanoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    Referring to risk of progression or recurrence.

  2. 2.

    Personal observation.

  3. 3.

    Personal observation.

  4. 4.

    Personal observation.

  5. 5.

    Personal observation.

  6. 6.

    FDA label (package insert) for Intron-A.

References

  1. SEER Cancer Statistics Review, 1975–2005. In, Vol. 2008: National Cancer Institute 2007.

    Google Scholar 

  2. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;92:2771–2776.

    Article  Google Scholar 

  3. Rigel DS, Friedman RJ, Kopf AW, et al. ABCDE—an evolving concept in the early detection of melanoma. Arch Dermatol. 2005;141:1032–1034.

    Article  PubMed  Google Scholar 

  4. Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol. 2005;52:109–121.

    Article  PubMed  Google Scholar 

  5. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45:579–586.

    Article  CAS  PubMed  Google Scholar 

  6. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol. 1998;134:569–572.

    Article  CAS  PubMed  Google Scholar 

  7. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2008.

    Google Scholar 

  8. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648.

    CAS  PubMed  Google Scholar 

  9. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149:66–69.

    Article  CAS  PubMed  Google Scholar 

  10. Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27–29, 1992. Consensus statement/NIH Consensus Development Conference 1992;10:1–25.

    Google Scholar 

  11. Bene NI, Healy C, Coldiron BM. Mohs Micrographic Surgery is Accurate 95.1% of the Time for Melanoma In Situ: A Prospective Study of 167 Cases. Dermatol Surg 2008.

    Google Scholar 

  12. Walling HW, Scupham RK, Bean AK, et al. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 2007;57:659–664.

    Article  PubMed  Google Scholar 

  13. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma: a follow-up study. Dermatol Surg. 1998;24:673–677.

    Article  CAS  PubMed  Google Scholar 

  14. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg. 2007;33:395–402.

    Article  CAS  PubMed  Google Scholar 

  15. Bricca GM, Brodland DG, Ren D, et al. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92–100.

    Article  PubMed  Google Scholar 

  16. Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140:1087–1092.

    Article  PubMed  Google Scholar 

  17. Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003;110:2011–2018.

    Article  PubMed  Google Scholar 

  18. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139:943–944.

    Article  PubMed  Google Scholar 

  19. Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485–488.

    Article  CAS  PubMed  Google Scholar 

  20. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15–21.

    Article  CAS  PubMed  Google Scholar 

  21. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34:147–151.

    Article  CAS  PubMed  Google Scholar 

  22. Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58:142–148.

    Article  PubMed  Google Scholar 

  23. Somach SC, Taira JW, Pitha JV, et al. Pigmented lesions in actinically damaged skin: histopathologic comparison of biopsy and excisional specimens. Arch Dermatol. 1996;132:1297–1302.

    Article  CAS  PubMed  Google Scholar 

  24. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. 1991;78:1108–1110.

    Article  CAS  PubMed  Google Scholar 

  25. Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol. 1985;13:983–987.

    Article  CAS  PubMed  Google Scholar 

  26. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol. 2002;46:690–694.

    Article  PubMed  Google Scholar 

  27. McKenna DB, Lee RJ, Prescott RJ, et al. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision. Br J Dermatol. 2004;150:523–530.

    Article  CAS  PubMed  Google Scholar 

  28. Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107:2647–2652.

    Article  PubMed  Google Scholar 

  29. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159–1162.

    Article  CAS  PubMed  Google Scholar 

  30. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1–4 mm): Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–267; discussion 7–9.

    Article  CAS  PubMed  Google Scholar 

  31. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328.

    Article  CAS  PubMed  Google Scholar 

  32. McKinnon JG, Starritt EC, Scolyer RA, et al. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg. 2005;241:326–333.

    Article  PubMed  Google Scholar 

  33. Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg. 1984;200:759–763.

    CAS  PubMed  Google Scholar 

  34. Aitken DR, Clausen K, Klein JP, et al. The extent of primary melanoma excision. A re-evaluation—how wide is wide? Ann Surg. 1983;198:634–641.

    Article  CAS  PubMed  Google Scholar 

  35. Ackerman AB, Scheiner AM. How wide and deep is wide and deep enough? A critique of surgical practice in excisions of primary cutaneous malignant melanoma. Hum Pathol. 1983;14:743–744.

    Article  CAS  PubMed  Google Scholar 

  36. Salopek TG, Slade JM, Marghoob AA, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma. J Am Acad Dermatol. 1995;33:451–461.

    Article  CAS  PubMed  Google Scholar 

  37. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001;45:260–276.

    Article  CAS  PubMed  Google Scholar 

  38. Nestle FO, Kerl H. Melanoma. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. Vol 2. 1st ed. New York, NY: Mosby; 2003:1789–1817.

    Google Scholar 

  39. Veronesi U, Adams J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I malignant melanoma of the skin of the lower extremities. Cancer. 1982;49:2420–2430.

    Article  CAS  PubMed  Google Scholar 

  40. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627–630.

    Article  CAS  PubMed  Google Scholar 

  41. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697–705.

    CAS  PubMed  Google Scholar 

  42. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1–4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263; discussion 63–66.

    Article  CAS  PubMed  Google Scholar 

  43. Landry CS, McMasters KM, Scoggins CR. The evolution of the management of regional lymph nodes in melanoma. J Surg Oncol. 2007;96:316–321.

    Article  PubMed  Google Scholar 

  44. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am. 2003;83:385–403.

    Article  PubMed  Google Scholar 

  45. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317.

    Article  CAS  PubMed  Google Scholar 

  46. Rex J, Paradelo C, Mangas C, et al. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg. 2005;31:1385–1393.

    Article  CAS  PubMed  Google Scholar 

  47. Gutzmer R, Al Ghazal M, Geerlings H, et al. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137–1141.

    Article  CAS  PubMed  Google Scholar 

  48. Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141:728–735.

    Article  PubMed  Google Scholar 

  49. White RR, Tyler DS. Management of node-positive melanoma in the era of sentinel node biopsy. Surg Oncol. 2000;9:119–125.

    Article  CAS  PubMed  Google Scholar 

  50. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15:670–673.

    Article  PubMed  Google Scholar 

  51. Willis AI, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck. 2007;29:979–985.

    Article  PubMed  Google Scholar 

  52. Kilpatrick LA, Shen P, Stewart JH, et al. Use of sentinel lymph node biopsy for melanoma of the head and neck. Am Surg. 2007;73:754–758; discussion 8–9.

    PubMed  Google Scholar 

  53. Morris KT, Stevens JS, Pommier RF, et al. Usefulness of preoperative lymphoscintigraphy for the identification of sentinel lymph nodes in melanoma. Am J Surg. 2001;181:423–426.

    Article  CAS  PubMed  Google Scholar 

  54. Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007;110:614–624.

    Article  PubMed  Google Scholar 

  55. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–258.

    Article  PubMed  Google Scholar 

  56. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449–458.

    Article  PubMed  Google Scholar 

  57. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13:533–541.

    Article  PubMed  Google Scholar 

  58. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617–621.

    Article  PubMed  Google Scholar 

  59. Corsetti RL, Allen HM, Wanebo HJ. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol. 2000;7:456–460.

    Article  CAS  PubMed  Google Scholar 

  60. Cuellar FA, Vilalta A, Rull R, et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res. 2004;14:277–282.

    Article  PubMed  Google Scholar 

  61. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18:1232–1242.

    Article  PubMed  Google Scholar 

  62. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100–108.

    Article  PubMed  Google Scholar 

  63. Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15:316–322.

    Article  PubMed  Google Scholar 

  64. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol. 2007;34:509–515.

    Article  PubMed  Google Scholar 

  65. Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J (Sudbury, Mass). 2007;13:217–222.

    Article  CAS  Google Scholar 

  66. Mendenhall W, Amdur R, Hinerman R, et al. Head and neck mucosal melanoma. Am J Clin Oncol. 2005;28:626–630.

    Article  PubMed  Google Scholar 

  67. Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.

    Article  CAS  PubMed  Google Scholar 

  68. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–319.

    Article  PubMed  Google Scholar 

  69. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004;11:1079–1084.

    Article  PubMed  Google Scholar 

  70. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555–4558.

    Article  PubMed  Google Scholar 

  71. Foote M, Burmeister B, Burmeister E, et al. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg. 2008;78:273–276.

    Article  PubMed  Google Scholar 

  72. Elias EG, Zapas JL, Beam SL, et al. Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up. Melanoma Res. 2007;17:310–315.

    Article  PubMed  Google Scholar 

  73. Morton DL. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Dev Biol (Basel ). 2004;116:209–217; discussion 29–36.

    CAS  Google Scholar 

  74. Eilber FR, Morton DL, Holmes EC, et al. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976;294:237–240.

    Article  CAS  PubMed  Google Scholar 

  75. Davis-Daneshfar A, Boni R, von Wussow P, et al. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. J Immunother. 1997;20:208–213.

    Article  CAS  PubMed  Google Scholar 

  76. Ridolfi L, Ridolfi R, Riccobon A, et al. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother. 2003;26:156–162.

    Article  CAS  PubMed  Google Scholar 

  77. Gardini A, Ercolani G, Riccobon A, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol. 2004;87:46–52.

    Article  PubMed  Google Scholar 

  78. Moschos S, Kirkwood J, Konstantinopoulos P. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004;22:11–14.

    Article  CAS  PubMed  Google Scholar 

  79. Hancock B, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53–61.

    Article  CAS  PubMed  Google Scholar 

  80. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677.

    Article  CAS  PubMed  Google Scholar 

  81. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991;18:83–90.

    CAS  PubMed  Google Scholar 

  82. Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142:433–438.

    Article  PubMed  Google Scholar 

  83. Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol. 2007;46:575–577.

    Article  PubMed  Google Scholar 

  84. Francken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol. 2008;34:587–592.

    CAS  PubMed  Google Scholar 

  85. Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol. 2001;8:658–662.

    Article  CAS  PubMed  Google Scholar 

  86. Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139:961–966; discussion 6–7.

    Article  PubMed  Google Scholar 

  87. Hena MA, Emrich LJ, Nambisan RN, et al. Effect of surgical treatment on stage IV melanoma. Am J Surg. 1987;153:270–275.

    Article  CAS  PubMed  Google Scholar 

  88. Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983–1991.

    Article  CAS  PubMed  Google Scholar 

  89. Gutman H, Hess KR, Kokotsakis JA, et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001;25:750–758.

    Article  CAS  PubMed  Google Scholar 

  90. de Wilt JH, McCarthy WH, Thompson JF. Surgical treatment of splenic metastases in patients with melanoma. J Am Coll Surg. 2003;197:38–43.

    Article  PubMed  Google Scholar 

  91. Boogerd W, De Gast G, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–312.

    Article  CAS  PubMed  Google Scholar 

  92. Kased N, Huang K, Nakamura J, et al. Gamma knife radiosurgery for brainstem metastases: the UCSF experience. J Neurooncol. 2008;86:195–205.

    Article  PubMed  Google Scholar 

  93. Majer M, Samlowski WE. Management of metastatic melanoma patients with brain metastases. Curr Oncol Rep. 2007;9:411–416.

    Article  CAS  PubMed  Google Scholar 

  94. Samlowski W, Watson G, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855–1862.

    Article  PubMed  Google Scholar 

  95. Mathieu D, Kondziolka D, Cooper P, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007;60:471–481; discussion 81–82.

    PubMed  Google Scholar 

  96. Agarwala SS. Relevance and necessity of studies on second-line chemotherapy in melanoma. Onkologie. 2004;27:527–528.

    Article  PubMed  Google Scholar 

  97. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs. 2005;6:1234–1239.

    CAS  PubMed  Google Scholar 

  98. Middleton MR, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer. 2000;82:1158–1162.

    Article  CAS  PubMed  Google Scholar 

  99. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen vs dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751.

    CAS  PubMed  Google Scholar 

  100. Lawson DH. Choices in adjuvant therapy of melanoma. Cancer Control. 2005;12:236–241.

    PubMed  Google Scholar 

  101. Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma–from deeply disappointing to bright future? Experimental Dermatology. 2008;17:383–394.

    Article  CAS  PubMed  Google Scholar 

  102. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23:6747–6755.

    Article  CAS  PubMed  Google Scholar 

  103. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol. 2006;17:571–577.

    Article  CAS  PubMed  Google Scholar 

  104. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11–S14.

    PubMed  Google Scholar 

  105. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26:955–962.

    Article  CAS  PubMed  Google Scholar 

  106. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25:8505.

    Google Scholar 

  107. Comin-Anduix B, Lee Y, Jalil J, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008;6:22.

    Article  PubMed  CAS  Google Scholar 

  108. Cohn M. What roles do regulatory T cells play in the control of the adaptive immune response? Int Immunol. 2008;20:1107–1118.

    Article  CAS  PubMed  Google Scholar 

  109. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38:921–924.

    Article  CAS  PubMed  Google Scholar 

  110. Gallimore A, Godkin A. Regulatory T cells and tumour immunity—observations in mice and men. Immunology. 2008;123:157–163.

    Article  CAS  PubMed  Google Scholar 

  111. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445–3455.

    Article  CAS  PubMed  Google Scholar 

  112. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.

    Article  CAS  PubMed  Google Scholar 

  113. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977.

    Article  CAS  PubMed  Google Scholar 

  114. Bulanhagui CA, Ribas A, Pavlov D, et al. Phase I clinical trials of ticilimumab: tumor responses are sufficient but not necessary for prolonged survival. J Clin Oncol. 2006;24:8036.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Associates of San Antonio, San Antonio, TX, USA

    Mark F. Naylor MD

Authors
  1. Mark F. Naylor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. One Hermann Museum Circle , Houston, 77004, U.S.A.

    Deborah F. MacFarlane

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Naylor, M.F. (2009). Practical Management of Melanoma. In: MacFarlane, D.F. (eds) Skin Cancer Management. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88495-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-88495-0_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-88494-3

  • Online ISBN: 978-0-387-88495-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation